9F1 — Diagonal Bio AB Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- €0.78m
- -€1.96m
- SEK0.06m
Annual income statement for Diagonal Bio AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 41 W | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.02 | 0.407 | 0.203 | 0.023 | 0.062 |
| Cost of Revenue | |||||
| Gross Profit | -6.38 | -15.5 | -11.5 | -9.57 | -5.58 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.604 | 12.1 | 15.4 | 11.6 | 9.48 |
| Operating Profit | -0.583 | -11.7 | -15.2 | -11.6 | -9.42 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.583 | -11.7 | -16.2 | -11.7 | -9.93 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.583 | -11.7 | -16.2 | -11.7 | -9.93 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.583 | -11.7 | -16.2 | -11.7 | -9.93 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.583 | -11.7 | -16.2 | -11.7 | -9.93 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.015 | -0.296 | -0.67 | -0.126 | -0.023 |
| Dividends per Share |